{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-005420","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.383588+00:00","generated_at":"2026-05-16T11:24:11.970253+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Monte Rosa reports positive interim Phase 1 data for MRT-8102; hsCRP reduced 85% in 4 weeks","bullets":["In subjects with elevated CVD risk, MRT-8102 reduced hsCRP by 85% after 4 weeks; 94% achieved hsCRP <2 mg/L (median baseline 6.3 mg/L).","NEK7 degradation ~80-90% in T cells across all dose levels (5-400 mg); favorable safety with mild/moderate AEs, no dose dependency.","Median IL-6 dropped 55% to below cardiovascular risk threshold; CSF IL-6 decreased 75% in two subjects, suggesting CNS effect.","Plan to initiate Phase 2 GFORCE-2 study in ASCVD in 2026; expand GFORCE-1 with readout H2 2026.","Also evaluating Phase 2 studies in MASH, gout, recurrent pericarditis; collaborator Novartis to initiate Phase 2 studies of MRT-6160 in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-005420","json":"https://secwatch.observer/filing/0001193125-26-005420.json","markdown":"https://secwatch.observer/filing/0001193125-26-005420.md","text":"https://secwatch.observer/filing/0001193125-26-005420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526005420/0001193125-26-005420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526005420/glue-20260107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:24:11.970253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}